Sign In


John P. Perentesis MD, FAAP

John P. Perentesis MD, FAAP
Professor/ Division DirectorCollege of Medicine--UCJohn.Perentesis@cchmc.org
CHRF-2372 Mail Location 7015 3333 Burnet Avenue Cincinnati OH 45229
Phone:513-636-6090Fax: 513-636-3549
  • Experimental Therapeutics
  • Pediatric Oncology (Developing)

Research Description

Dr. Perentesis' clinical research focuses on the development of molecularly targeted therapies for pediatric and adolescent cancer. His laboratory program focuses on complementary studies of leukemia biology and pharmacogenetics of childhood cancer therapy. The laboratory has developed novel recombinant anticancer drugs, and discovery of genes involved in cellular regulation. Dr. Perentesis is also committed to expansion of the zebrafish model system in oncology.

Current Publications

  • Gamis AS, Alonzo TA, Perentesis JP, Meshinchi SChildren's Oncology Group's 2013 blueprint for research: Acute myeloid leukemia.Pediatr Blood Cancer 60(6) 964-71 6/1/2013
  • Phillips CL, Davies SM, McMasters R, Absalon M, O'Brien M, Mo J, Broun R, Moscow JA, Smolarek T, Garzon R, Blum W, Schwind S, Marcucci G, Perentesis JPLow dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults.Br J Haematol 161(3) 406-10 5/1/2013
  • Cooper TM, Razzouk BI, Gerbing R, Alonzo TA, Adlard K, Raetz E, Gamis AS, Perentesis JP, Whitlock JAPhase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): A report from the Children's Oncology Group.Pediatr Blood Cancer in press 1/17/2013
  • Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, Brell JM, Siu LLManagement of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway.J Clin Oncol 30(23) 2919-28 8/10/2012
  • Chang KH, Sanchez-Aguilera A, Shen S, Sengupta A, Madhu MN, Ficker AM, Dunn SK, Kuenzi AM, Arnett JL, Santho RA, Agirre X, Perentesis JP, Deininger MW, Zheng Y, Bustelo XR, Williams DA, Cancelas JAVav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival.Blood 120(4) 800-11 7/26/2012
  • Dorris K, Fouladi M, Davies SM, Perentesis JP, Lawrence JM, Chow LM, Assa'ad A, Uygungil B, Jodele SSevere allergic reactions to thiol-based cytoprotective agents mesna and amifostine in a child with a supratentorial primitive neuroectodermal tumor.J Pediatr Hematol Oncol 33(6) e250-2 8/1/2011
  • Davies SM, Perentesis JPTribute: the American Society of Pediatric Hematology/Oncology (ASPHO), 2011 Distinguished Career Award goes to Dr. William G. Woods.Pediatr Blood Cancer 56(6) 895-6 6/1/2011